Wong Ru Xin, Low Hui Ying Terese, Tan Daniel Yat Harn
Department of Radiation Oncology, National Cancer Centre Singapore, Singapore.
Department of Otorhinolaryngology, National University Hospital, Singapore.
Singapore Med J. 2018 Nov;59(11):590-596. doi: 10.11622/smedj.2018107. Epub 2018 Sep 5.
There are many treatment options for vestibular schwannomas (VSs), including radiosurgery. Previous studies have shown good outcomes for smaller tumours. We report the results of a seven-year cohort of patients with VS who were treated at our centre using a linear accelerator-based stereotactic radiosurgery system.
We retrospectively reviewed the case notes and magnetic resonance (MR) images of patients with VS treated with radiosurgery. Treatment was administered as either a single 13 Gy session or 25 Gy in five sessions. At our centre, only larger or higher Koos grade VSs, were routinely treated with hypofractionated radiosurgery. Tumour response and hearing were assessed using RECIST criteria and Gardner-Robertson scale, respectively. Other toxicities were assessed using physical examination and history-taking. Freedom from radiological progression was estimated with the Kaplan-Meier method.
46 patients received single-fraction radiosurgery and 31 received hypofractionated radiosurgery. Median follow-up duration was 40.6 months. 29 patients had prior surgery to remove the tumour (median size 1.68 cm3). One patient who had symptomatic increase in tumour size (> 20% in largest diameter) was treated conservatively and subsequently showed stable disease on MR imaging. Progression-free survival was 98.7%. Another patient had symptomatic oedema requiring ventriculoperitoneal shunt insertion. 11 patients had serviceable hearing before radiotherapy and 72.7% of them retained useful hearing (20.1 dB mean decline in pure tone average). Facial and trigeminal nerve functions and sense of equilibrium were preserved in > 90% of patients.
Radiosurgery is effective and safe for small VSs or as an adjunct therapy after microsurgery.
前庭神经鞘瘤(VS)有多种治疗选择,包括放射外科治疗。既往研究表明,较小的肿瘤采用放射外科治疗效果良好。我们报告了在我们中心使用基于直线加速器的立体定向放射外科系统治疗的VS患者的七年队列研究结果。
我们回顾性分析了接受放射外科治疗的VS患者的病历和磁共振(MR)图像。治疗方式为单次13 Gy照射或分五次给予25 Gy照射。在我们中心,只有较大的或Koos分级较高的VS才常规采用大分割放射外科治疗。分别使用实体瘤疗效评价标准(RECIST)和Gardner-Robertson量表评估肿瘤反应和听力。通过体格检查和病史采集评估其他毒性反应。采用Kaplan-Meier法估计无放射学进展生存率。
46例患者接受了单次分割放射外科治疗,31例接受了大分割放射外科治疗。中位随访时间为40.6个月。29例患者曾接受过肿瘤切除术(中位大小为1.68 cm³)。1例肿瘤大小出现有症状性增大(最大直径增加>20%)的患者接受了保守治疗,随后磁共振成像显示病情稳定。无进展生存率为98.7%。另1例患者出现有症状性水肿,需要插入脑室腹腔分流管。11例患者放疗前听力尚可,其中72.7%的患者保留了有用听力(纯音平均听阈平均下降20.1 dB)。>90%的患者保留了面神经、三叉神经功能和平衡感。
放射外科治疗对小型VS或作为显微手术后的辅助治疗有效且安全。